Gene therapy for rare diseases marks a new era in precision medicine: Insights from clinical trials

Molecular Restoration Through Replacement Therapies: Current Advances and Future Directions in Treating Diseases

Replacement therapy is an advanced therapeutic approach for diseases caused by molecular deficits. It aims to restore normal physiology by replacing deficient molecules such as enzymes, proteins, genes, or other molecules. Here, we discuss different modalities, including protein replacement, gene therapy, messenger RNA (mRNA) replacement, noncoding RNA (ncRNA) therapies, cell replacement, and gene editing, aimed at addressing and treating the fundamental genetic defects underlying a range of diseases. These therapies could have potentially curative and disease-modifying effects when used to directly replace deficient or dysfunctional components, addressing the inherent limitations of conventional therapies, such as off-target effects and control of disease-related symptoms. Some replacement therapies, such as protein therapy, gene therapy, and cell therapy, are already approved for clinical use, while emerging approaches—including mRNA therapy, ncRNA therapy, and gene editing—remain primarily in the preclinical or clinical trial stages. To achieve broad clinical translation of these emerging approaches, key challenges, including delivery, safety, specificity, and ethical concerns, must be addressed. This review provides an overview of the existing modalities of replacement therapies, their mechanisms of action, and future directions for improving clinical translation, efficacy, and accessibility.

Gene Therapy in Heart Failure: A Systematic Review of Therapeutic Potential, Limitations, and Future Directions

Gene therapy clinical trials for inherited eye diseases: The pediatric perspective.

Gene therapy is an increasingly useful treatment option, especially in children, where most inherited diseases manifest. This review provides a literature synthesis of current gene therapy treatments in pediatric ophthalmology. Our search encompassed the ClinicalTrials.gov database. Sixteen clinical trials with published results reporting gene therapy for genetic ocular diseases in children (under 18 years) were included. Diseases under investigation for gene therapy in children included Leber's Congenital Amaurosis (CEP290, RPE65 genes), Leber's Hereditary Optic Neuropathy (ND4), Retinitis Pigmentosa (MERTK), Usher Syndrome Type 2 (USH2A), X-linked Retinitis Pigmentosa (RPGR), Achromatopsia (CNGA3, CNGB3), and X-linked Retinoschisis (RS1). Most clinical trials in our search were in Phases 1 or 2, with five studies having progressed to Phase 3. In certain cases, treatment demonstrated encouraging results, providing the patients with an improvement in BCVA, retinal sensitivity, and quality of life. However, the outcome measures regarding the efficacy and tolerability of gene therapy varied and some studies noted adverse events. Clinical trials that have yet to publish their results were also recorded. While the field of pediatric ophthalmology shows promise for gene therapy options, future strategies should include stratified enrollment based on age, separate cohorts for pediatric and adult patients, or adaptive trial designs.

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach

Gene- and cell-based therapies (GCTs) represent a disruptive and transformative class of biomedical innovations. They address diseases by adding, removing, repairing, or replacing genes and/or by endowing distinct living cells with additional biological functions. Through this plethora of options, numerous conditions—including genetic disorders, cancers, and degenerative diseases—have become potential targets for a curative therapy. Thus, GCTs are considered the “Future of Medicine” as they (i) offer a potential cure, particularly for rare and severe disorders previously considered untreatable, (ii) expand the treatment options for common diseases, and (iii) possess the possibility to complement currently applied conventional treatment options. Recognizing both the scientific promise and translational challenges of GCTs, Germany has launched a coordinated national initiative—the National Strategy for Gene- and Cell-Based Therapies. The Strategy was commissioned by the German Federal Ministry of Research, Technology and Space (BMFTR, formerly the German Federal Ministry of Education and Research [BMBF]) and developed through a multi-stakeholder process. The latter involved more than 150 experts from academia, industry, health care sector, professional associations, and patient organizations, who were nominated by the community and assembled into eight working groups to identify current roadblocks and propose possible solutions. Summarized in the Strategy Paper, which was submitted to the BMFTR and published on June 12, 2024, a comprehensive roadmap was developed in this bottom-up process to accelerate the development and clinical implementation of GCTs in Germany. Although it initially had a national focus, the resulting framework is increasingly contributing to the international GCT landscape through growing exchange with GCT initiatives launched in other European member states and with the European Society of Gene and Cell Therapy (ESGCT). In brief, the initiative is focusing on translation starting from research through all steps to clinical application and beyond. This includes workforce development, regulatory frameworks, manufacturing capacity, patient access, and communication with the general public. Numerous targeted measures have been developed by the participating experts in the working groups and are currently being implemented in this broad, collaborative, and bottom-up multi-stakeholder approach. They encompass, for example, the establishment of a website as central information platform, including the GCT-Atlas, a web-based networking and information tool for stakeholders and actors in the GCT field, tailored communication and outreach formats, a Regulatory Support Unit providing independent regulatory guidance for publicly funded early-stage, nonclinical product development, different funding and entrepreneurship programs offering researchers and clinicians financial, educational, and mentoring support, as well as the establishment of translational infrastructure and exchange formats with investors to specifically foster the necessary scale-up and commercialization. Overall, the main goal of the German National Strategy for GCT is to ensure patient access to advanced therapies while strengthening Germany’s position as an international hub for biomedical innovation. To accomplish this, existing resources need to be coordinated, streamlined, and prioritized to increase efficiency and support the long-term sustainability of the system. These objectives are closely aligned with current emerging European initiatives, including the EU Biotech Act and the Horizon Europe work program 2026, which aim to further optimize the framework conditions for this strategically important field and enhance future European competitiveness.

AAV-mediated genetic interventions in the treatment of rare kidney disease: a narrative review

The current advancements in gene therapy mediated by rAAV vectors for rare kidney disease, particularly monogenic kidney diseases that lead to CKD, are summarized, and the future directions in this field are discussed.

Therapeutic Advances and Novel Drug Treatment Opportunities in the Neuromuscular Disorders Area